-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
There are few treatment options for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
Lymphoma Epcoritamab is a new bispecific antibody targeting CD3 and CD20, which can induce T cell-mediated cytotoxic activity against CD20+ malignant B cells
In the dose escalation phase of this Phase 1/2 study, relapsed/refractory CD20+ B-cell Fehodgkin’s lymph nodes were recruited from 10 locations in 4 countries (Denmark, Netherlands, United Kingdom, and Spain) over 18 years of age Tumor patients
immunity
From June 26, 2018 to July 14, 2020, a total of 73 patients with relapsed, advanced or refractory CD20+ mature B-cell non-Hodgkin’s lymphoma were recruited, of which 68 received an escalating full dose of Epcoritamab (0.
The occurrence of adverse events
The occurrence of adverse events68 patients who received at least one dose of Epcoritamab were included in the safety analysis: the most common adverse events were fever (69%), cytokine release syndrome (CRS, 59%; all grades 1-2) and injection site reactions (47%)
The most common adverse events were fever (69%), cytokine release syndrome (CRS, 59%; all grades 1-2), and injection site reactions (47%).
Progression-free survival rate of patients with diffuse large B-cell lymphoma
Progression-free survival rate of patients with diffuse large B-cell lymphomaThe overall response rate for patients with relapsed/refractory diffuse large B-cell lymphoma was 68% (95% CI 45-86), of which 45% were complete responses (full dose 12-60 mg)
The overall response rate for patients with relapsed/refractory diffuse large B-cell lymphoma was 68% (95% CI 45-86), of which 45% were complete remission of relapsed/refractory diffuse large B-cell lymphoma The overall response rate of patients was 68% (95% CI 45-86), of which 45% were complete remission of relapsed/refractory follicular lymphoma.
Epcoritamab single-drug subcutaneous injection in the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma is safe and well tolerated, and has shown preliminary anti-tumor activity.
Original source:
Martin Hutchings, et al.
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
in this message
